CellSource (4880) FY2026 Q1 Earnings Report

Quick View

Executive Summary

FY2026 Q1 results: Revenue 860 million yen (YoY +1.3%), Operating Income 59 million yen (YoY +195.2%), Ordinary Income 59 million yen (YoY +198.3%), Net Income 34 million yen (YoY +173.9%). The company achieved a turnaround to profitability from prior year losses. Gross profit margin remained high at 59.2% with gross profit of 509 million yen. SG&A expenses decreased to 450 million yen (52.3% of revenue) from 528 million yen in the prior period, driving the operating profit improvement. The company maintains a single segment structure in regenerative medicine-related business. Non-operating income and expenses were minimal at 4 million yen and 4 million yen respectively. Extraordinary loss of 12 million yen was recorded, primarily from impairment losses, while extraordinary income of 3 million yen included reversal of subscription rights. The profitability recovery occurred despite essentially flat revenue growth, indicating improved operating leverage through cost management.

Performance Drivers

Revenue increased marginally by 1.3% to 860 million yen, representing near-flat top-line performance. The company operates solely in the regenerative medicine-related business segment with no diversification. Cost of sales decreased to 351 million yen from 383 million yen YoY, improving gross profit to 509 million yen (gross margin 59.2%) from 466 million yen (54.9%) in the prior period. This 4.3 percentage point gross margin expansion reflects improved production efficiency or pricing power. The key profit driver was SG&A expense reduction of 78 million yen (down 14.8% YoY) to 450 million yen, bringing the SG&A ratio down to 52.3% from 62.2%. This significant operating expense discipline transformed a 62 million yen operating loss into a 59 million yen operating profit. Non-operating items were minimal, with non-operating income of 4 million yen and non-operating expenses of 4 million yen, resulting in ordinary income closely aligned with operating income at 59 million yen. Extraordinary items included impairment loss of 12 million yen as a non-recurring factor, offset partially by 3 million yen in gains from reversal of subscription rights. After tax expenses of 17 million yen (effective tax rate 34%), net income reached 34 million yen versus a 45 million yen loss in the prior period. The profit turnaround follows a "revenue stable/profit up" pattern, driven primarily by gross margin expansion and SG&A cost control rather than top-line growth. The sustainability of this profit recovery depends on whether the cost reductions represent structural improvements or temporary measures, given the full-year forecast still projects an operating loss of 170 million yen.

Key Metrics

[Profitability] ROE of 0.6% represents a significant improvement from negative territory in the prior period but remains extremely low, reflecting limited return generation on the 5.95 billion yen equity base. Operating margin of 6.9% improved substantially from negative 7.3% YoY, demonstrating operational recovery. Gross profit margin of 59.2% expanded 4.3 percentage points from 54.9%, indicating strong pricing power or cost management in the core regenerative medicine business. However, the net profit margin of 3.9% remains modest despite the turnaround. [Cash Quality] Cash and deposits of 4.63 billion yen represent 67.1% of total assets, providing exceptional liquidity strength. Short-term debt coverage stands at approximately 121 times (cash/current liabilities), indicating robust ability to meet near-term obligations. [Investment Efficiency] Total asset turnover of 0.125 (annualized basis) remains very low, reflecting the capital-light nature of assets dominated by cash holdings rather than productive operating assets. Working capital management shows room for improvement with trade receivables at 291 million yen and inventories totaling 264 million yen (finished goods 77 million yen, work in process 42 million yen, raw materials 144 million yen). [Financial Health] Equity ratio of 86.3% indicates an extremely conservative capital structure with minimal leverage. Current ratio of approximately 1,395% (5.34 billion yen current assets / 383 million yen current liabilities) demonstrates exceptionally strong short-term solvency. Debt-to-equity ratio of 0.16 reflects negligible financial leverage. The balance sheet shows 6.89 billion yen in total assets against only 942 million yen in liabilities. Intangible assets increased significantly to 136 million yen from 56 million yen YoY, potentially reflecting development investments requiring monitoring for impairment risk.

Cash Flow Analysis

Cash and deposits decreased by 87 million yen to 4.63 billion yen from 4.71 billion yen YoY, representing a 1.8% decline despite the return to profitability. Total assets decreased by 131 million yen to 6.89 billion yen, driven by reductions in current assets which fell to 5.34 billion yen from 5.49 billion yen. Within working capital, trade receivables decreased by 47 million yen to 291 million yen, improving collection efficiency. Inventories declined by 12 million yen to 264 million yen, showing marginally better inventory management. On the liability side, current liabilities decreased to 383 million yen from 443 million yen, including a reduction in income taxes payable from 28 million yen to 15 million yen and provision for bonuses declining from 63 million yen to 29 million yen, suggesting lower accrued compensation. Trade payables increased slightly by 5 million yen to 67 million yen. Non-current liabilities decreased marginally to 559 million yen from 564 million yen, primarily asset retirement obligations of 302 million yen. The balance sheet changes indicate modest cash consumption despite positive net income, likely reflecting timing differences in working capital and expense accruals. Property, plant and equipment declined to 937 million yen from 989 million yen, suggesting depreciation exceeded capital expenditures. Intangible assets increased substantially by 80 million yen to 136 million yen, representing significant investment in development or licensing activities. The cash coverage ratio remains exceptionally strong at over 12 times current liabilities, maintaining substantial financial flexibility despite the modest cash decline.

Earnings Quality

Ordinary income of 59 million yen versus operating income of 59 million yen shows virtually no contribution from non-operating items, indicating core business operations drove the profitability recovery. Non-operating income totaled 4 million yen, primarily miscellaneous income of 2 million yen, while non-operating expenses of 4 million yen included minimal interest expense of 0.3 million yen. The near-zero net non-operating impact represents less than 0.5% of revenue, demonstrating that earnings quality is primarily based on operating performance rather than financial engineering or extraordinary items. Extraordinary items showed a net loss of 9 million yen, comprising impairment losses of 12 million yen partially offset by gains on asset sales of 2 million yen and reversal of subscription rights of 3 million yen. The impairment loss represents a non-recurring factor that should be excluded when assessing normalized profitability. Tax expense of 17 million yen on pretax income of 51 million yen represents an effective tax rate of approximately 34%, which is reasonable and suggests no significant deferred tax benefits artificially boosting net income. The alignment between operating income and ordinary income, combined with minimal reliance on non-operating gains, indicates solid earnings quality from core operations. However, the significant SG&A reduction driving the profit turnaround warrants monitoring to ensure sustainability. Without access to operating cash flow data for the quarter, a full accruals assessment cannot be performed, though the balance sheet shows working capital management improvements that suggest cash generation potential.

Guidance Update

Full-year forecast projects revenue of 3.42 billion yen (YoY decline of 7.9%), operating loss of 170 million yen, ordinary loss of 164 million yen, and net loss of 136 million yen with EPS of negative 6.90 yen. Q1 revenue of 860 million yen represents 25.1% progress toward the annual target, in line with a standard quarterly run rate. However, Q1 operating profit of 59 million yen contrasts sharply with the full-year operating loss forecast of 170 million yen, implying the company expects significant deterioration in subsequent quarters totaling approximately 229 million yen in combined operating losses for Q2-Q4. This guidance assumes substantial negative seasonality or planned investments in later periods. No forecast revision was made this quarter despite the Q1 profit turnaround, suggesting management maintains a conservative outlook. The annual revenue forecast implies a significant decline from prior year levels, indicating expected business headwinds or strategic repositioning. The divergence between Q1 profitability and full-year loss guidance represents a critical monitoring point, as it suggests either temporary cost deferrals in Q1, expected revenue decline in later quarters, or planned stepped-up investments. Dividend forecast remains at zero yen, consistent with the projected annual loss and conservative capital allocation during the business transition period.

Risk Factors

Single segment concentration risk in regenerative medicine-related business exposes the company to sector-specific regulatory, technological, and market adoption challenges without diversification benefits. With total assets of 6.89 billion yen entirely dependent on this single business line, any adverse developments in regenerative medicine commercialization, reimbursement policies, or competitive dynamics would directly impact the entire enterprise. Asset efficiency and capital deployment risk evidenced by exceptionally low ROE of 0.6% and total asset turnover of 0.125, with 67% of assets held as cash earning minimal returns. Despite strong financial health, the company has yet to demonstrate effective deployment of its 4.63 billion yen cash position into value-creating investments, raising questions about strategic capital allocation. Intangible assets increased 141% to 136 million yen, suggesting increased development investments or licensing activities that carry execution risk and potential impairment if commercial milestones are not achieved. Operating leverage sustainability risk from the divergence between Q1 profitability (59 million yen operating income) and full-year loss guidance (170 million yen operating loss), implying significant quarterly volatility or planned investments that may pressure margins. The SG&A reduction of 78 million yen driving Q1 profit recovery requires validation as a sustainable structural improvement rather than temporary cost deferral.

Industry Benchmark (Reference - Proprietary Data)

[Industry Position] (Reference - Proprietary Analysis)

Cellsource operates in the regenerative medicine sector with highly specialized business characteristics. The company's operating margin of 6.9% and net profit margin of 3.9% reflect early-stage commercialization dynamics typical of regenerative medicine businesses, which often experience extended periods of investment and regulatory development before achieving stable profitability. The company's equity ratio of 86.3% significantly exceeds typical biotech/medtech industry levels of 60-70%, indicating exceptionally conservative financing with minimal leverage utilization. ROE of 0.6% falls well below regenerative medicine sector benchmarks, which typically range from 5-15% for established players, reflecting the company's challenge in generating returns on its substantial equity base. The cash-heavy balance sheet with 67% of assets in cash and deposits is characteristic of pre-commercial or early commercial-stage life science companies maintaining financial flexibility for R&D and regulatory activities, though it also indicates underutilized capital. Asset turnover of 0.125 is low even by capital-light biotech standards, suggesting the company is in a transitional phase between development and commercial scaling. The single-segment focus is common among specialized regenerative medicine companies but concentrates business risk. Industry data suggests that companies successfully transitioning from development to commercial operations typically show improving operating margins (moving from negative to 10-15% range) and accelerating revenue growth (15-30% annually), benchmarks against which Cellsource's flat revenue growth and projected full-year losses indicate ongoing commercialization challenges.

(Industry: Regenerative Medicine/Biotechnology sector characteristics, Comparison: Early commercial-stage biotech financial profiles, Source: Proprietary analysis)

Key Takeaways from Earnings

Profitability inflection achieved with Q1 turnaround to operating profit of 59 million yen from 62 million yen loss, driven by 4.3 percentage point gross margin expansion to 59.2% and 14.8% SG&A reduction, though sustainability remains uncertain given full-year loss guidance. This represents a critical monitoring point for whether operational improvements are structural or temporary. Exceptional financial safety with equity ratio of 86.3%, cash holdings of 4.63 billion yen covering current liabilities 12 times over, and debt-to-equity ratio of only 0.16, providing substantial runway for continued business development without near-term financing pressure. However, this financial strength contrasts sharply with ROE of 0.6% and asset turnover of 0.125, indicating significant underutilization of capital resources. Intangible asset investment acceleration with 141% increase to 136 million yen suggests intensified development or partnership activities that could drive future growth but also introduce execution risk and potential impairment exposure requiring close monitoring of commercialization milestones and asset quality.

---

This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Financial Analysis

Executive Summary

FY2026 Q1 represented a return to profitability for CellSource, although the recovery was driven primarily by cost discipline rather than top-line growth. Revenue increased only 1.3% YoY to JPY0.86bn. Gross profit rose 9.3% YoY to JPY0.51bn as cost of sales declined 8.5% to JPY0.35bn. The gross margin expanded by approximately 435bp YoY to 59.2%. SG&A expenses fell 14.8% YoY to JPY0.45bn, substantially faster than the modest revenue increase. Consequently, operating income improved to JPY0.06bn from an operating loss of JPY0.06bn in the prior-year quarter. The operating margin improved by approximately 1,416bp YoY to 6.9%, but remains below the 8-15% range generally considered solid profitability. Ordinary income was also JPY0.06bn, indicating that the Q1 operating recovery was not dependent on non-operating gains. Net income reached JPY0.03bn, compared with a JPY0.05bn loss a year earlier. Net margin improved by approximately 926bp YoY to 3.8%, although it remains below the 5% threshold associated with stronger earnings quality. A JPY0.12bn impairment loss, partly offset by JPY0.03bn of extraordinary income, reduced profit before tax to JPY0.05bn from JPY0.06bn of operating income. The reported one-time-items alert is material because gross extraordinary items equal 35.3% of net income; the impairment makes reported net income less reflective of underlying operating earnings in the quarter. The balance sheet remains exceptionally liquid, with JPY4.63bn of cash and deposits and a 1,395.1% current ratio. Financial leverage is limited, with a debt-to-equity ratio of 0.16x and interest coverage of 200.68x. However, the company maintains full-year guidance for a JPY1.70bn operating loss and JPY1.36bn net loss despite the Q1 profit, implying a significant deterioration in earnings during the remaining quarters. Q1 revenue progress of 25.2% is broadly aligned with the standard 25% first-quarter pace, but the expected full-year loss makes the durability of the cost-led Q1 recovery the central issue.

Profitability Analysis

The annualized DuPont ROE is 2.2%, comprising a 3.8% net profit margin, 0.499x asset turnover, and 1.16x financial leverage. The low annualized ROE is principally attributable to modest net profitability and low asset turnover, rather than insufficient leverage. Financial leverage is conservative and is not a constraint from a solvency perspective, but it also does not amplify shareholder returns materially. The most significant YoY change was in operating profitability: gross margin rose to 59.2% from approximately 54.9%, while SG&A declined 14.8% despite revenue growth of only 1.3%. SG&A represented 52.3% of revenue, down from approximately 62.2% in the prior-year quarter, creating roughly 990bp of operating leverage. This SG&A reduction, together with gross-margin improvement, converted a JPY0.62bn operating loss into JPY0.59bn operating income. The operating margin of 6.9% is a clear improvement but remains below the company's full potential if the business is to achieve sustainably attractive returns on its substantial cash-rich asset base. The annualized 0.499x asset turnover also reflects a large balance of idle or low-yielding cash relative to quarterly sales. The tax burden was 0.648, equivalent to an effective tax rate of 34.0%, which moderated conversion from pre-tax income to net income. The 0.863 interest-burden ratio reflects the gap between EBIT and profit before tax, including extraordinary items; actual financing pressure is low given only JPY0.003bn of interest expense. The JPY0.12bn impairment loss is the main drag between recurring operating profit and reported profit before tax. Therefore, the Q1 operating turnaround appears more robust than the net-income figure alone suggests, but its sustainability depends on whether gross-margin gains and SG&A restraint can persist while revenue resumes growth.

Growth Assessment

Revenue growth of 1.3% YoY was subdued, indicating that the Q1 earnings recovery cannot yet be characterized as demand-led expansion. Gross profit increased faster than revenue because cost of sales fell to JPY0.35bn from JPY0.38bn, lifting the gross margin to 59.2%. The company operates solely in the regenerative-medicine-related business, making growth dependent on demand trends, customer adoption, reimbursement and regulatory conditions within this single operating domain. Inventory declined 13.6% YoY to JPY0.77bn, while raw materials rose 5.3% to JPY1.44bn and work in process increased 6.3% to JPY0.42bn. This mix may indicate production inputs being held ahead of completion or shipment, and should be monitored against future sales growth. Full-year revenue guidance is JPY3.42bn, down 7.9% YoY, so management is not forecasting a broad-based growth recovery in FY2026. Q1 revenue represents 25.2% of the full-year forecast, essentially in line with the standard 25% Q1 progress rate. In contrast, Q1 operating income of JPY0.06bn compares with guidance for a JPY1.70bn full-year operating loss, indicating that forecasted losses are heavily weighted to the remaining quarters. The unchanged forecast heightens uncertainty over whether Q1 cost improvements are recurring, whether anticipated expenses will accelerate, or whether sales mix will weaken later in the year. The current profit quality is therefore better at the gross-profit and operating-profit levels than the full-year outlook implies, but the low revenue-growth base limits visibility on sustained earnings expansion.

Financial Health

Financial health is strong on liquidity and conservative on leverage. Current assets totaled JPY5.34bn against current liabilities of JPY0.38bn, resulting in working capital of JPY4.96bn and a current ratio of 1,395.1%. The quick ratio was similarly very high at 1,374.9%, supported primarily by JPY4.63bn of cash and deposits. Cash alone was more than twelve times current liabilities, indicating no apparent near-term maturity mismatch. Total liabilities were JPY0.94bn, equivalent to 13.7% of total assets, while total equity was JPY5.95bn. The debt-to-equity ratio of 0.16x is well below the 2.0x level associated with aggressive balance-sheet risk. Interest coverage of 200.68x further indicates that financing costs are immaterial relative to operating profit. Total assets declined JPY1.31bn YoY, principally because cash and deposits decreased JPY0.87bn and property, plant and equipment decreased JPY0.52bn. Intangible assets increased JPY0.80bn YoY, or 141.1%, to JPY1.36bn; although this equals only 2.0% of total assets, the increase warrants monitoring for economic benefit realization and future impairment exposure. Asset retirement obligations were JPY3.02bn, equal to 32.1% of total liabilities. This high ARO-to-liabilities ratio is the root cause of the HIGH_ARO_RATIO alert: noncurrent obligations are substantially influenced by restoration and decommissioning commitments rather than conventional operating payables. Such obligations are structurally relevant for a facility- and manufacturing-related regenerative-medicine business, but they reduce flexibility if sites are reconfigured, closed, or require accelerated remediation. The large cash position substantially mitigates the immediate financial impact of these obligations.

Notable B/S Changes

Intangible assets: +JPY0.80bn (+141.1%) to JPY1.36bn - the increase remains modest at 2.0% of total assets, but requires monitoring for returns generation and potential future impairment. Cash and deposits: -JPY0.87bn (-1.8%) to JPY4.63bn - liquidity remains exceptionally strong despite the decline. Property, plant and equipment: -JPY0.52bn (-5.2%) to JPY9.37bn - the reduction may reflect depreciation or asset rationalization and should be assessed alongside manufacturing capacity requirements. Total liabilities: -JPY0.65bn (-6.5%) to JPY9.42bn - lower liabilities support the already conservative capital structure, although asset retirement obligations of JPY3.02bn remain material.

Cash Flow Quality

The quarter's operating recovery is visible in income-statement profitability, with operating income of JPY0.06bn and net income of JPY0.03bn. Reported net income was reduced by a JPY0.12bn impairment loss, partly offset by JPY0.03bn of extraordinary income, so the quarter includes a material non-recurring component. The HIGH_ONE_TIME_ITEMS alert is relevant because gross extraordinary items represented 35.3% of net income, making bottom-line earnings less comparable with a purely recurring result. In particular, the impairment loss is economically adverse even though it is non-cash at recognition, as it indicates that the carrying value of an asset was not fully recoverable. Profit before tax of JPY0.05bn was below operating income of JPY0.06bn, reflecting the net adverse effect of extraordinary items rather than interest costs. The modest JPY0.003bn interest expense is immaterial to earnings capacity. Inventory was lower YoY, while receivables declined 13.9% YoY to JPY0.29bn, which is consistent with limited balance-sheet strain from sales-related working capital. The rise in raw materials and work in process should nevertheless be tracked against subsequent revenue and gross-margin trends because the company operates in a manufacturing-linked regenerative-medicine field. The cash balance of JPY4.63bn provides a substantial buffer against operating volatility and potential investment requirements.

Dividend Sustainability

The full-year forecast specifies a dividend per share of JPY0.0. Accordingly, there is no forecast dividend payout requirement against earnings or liquidity in FY2026. Retaining cash is consistent with the company's forecast full-year net loss of JPY1.36bn and with the need to preserve financial flexibility in a specialized regenerative-medicine business. The JPY4.63bn cash balance and low leverage provide capacity to absorb near-term losses without relying on external financing. However, a resumption of dividends would require evidence that the Q1 return to operating profitability can be sustained through the full fiscal year and that impairment-related charges do not recur. With no forecast dividend, the dividend payout ratio is effectively 0% on the stated FY2026 plan.

Risk Assessment

Business risks include Revenue concentration: the company has a single regenerative-medicine-related operating segment, leaving earnings exposed to demand, customer adoption, pricing, reimbursement, and regulatory changes in one business domain., Growth risk: Q1 revenue grew only 1.3% YoY, while full-year revenue guidance calls for a 7.9% YoY decline, limiting confidence that the Q1 profit turnaround reflects a durable demand recovery., Operating-cost reversal risk: the Q1 recovery depended heavily on a 14.8% reduction in SG&A and lower cost of sales; subsequent expense normalization could reverse the 6.9% operating margin., Manufacturing and quality-compliance risk: regenerative-medicine-related operations are exposed to manufacturing process reliability, product quality controls, facility compliance, and potentially costly remediation requirements..

Financial risks include Forecast-loss risk: the unchanged FY2026 forecast for a JPY1.70bn operating loss and JPY1.36bn net loss contrasts sharply with Q1 operating profit, implying substantial earnings pressure in the remaining quarters., Impairment risk: Q1 included a JPY0.12bn impairment loss, and intangible assets increased 141.1% YoY to JPY1.36bn; future recoverability assessments remain relevant., Asset-retirement-obligation risk: AROs of JPY3.02bn represent 32.1% of total liabilities, making restoration obligations a material component of long-term commitments., Low-return capital structure: annualized ROE of 2.2% and annualized asset turnover of 0.499x indicate that the substantial cash and asset base is currently generating limited shareholder returns..

Key concerns include The highest-priority issue is the divergence between positive Q1 operating income of JPY0.06bn and guidance for a full-year JPY1.70bn operating loss., The second priority is whether the gross-margin improvement to 59.2% and SG&A reduction can be maintained without impairing commercial execution or future growth., The third priority is the economic significance of the JPY0.12bn impairment loss and the subsequent performance of the assets underlying the increased intangible-asset balance., The HIGH_ONE_TIME_ITEMS alert reduces confidence in using reported net income alone as a measure of recurring earnings., The HIGH_ARO_RATIO alert highlights long-dated facility-related obligations, although immediate liquidity risk is mitigated by the large cash balance..

Investment Implications

Key takeaways include Q1 returned to operating and net profitability, with operating income improving to JPY0.06bn from a JPY0.06bn loss., Margin recovery was substantial: gross margin increased to 59.2% and operating margin reached 6.9%., The turnaround was driven more by cost reduction than revenue growth, as sales increased only 1.3% YoY., Liquidity is exceptionally strong, with JPY4.63bn of cash, a 1,395.1% current ratio, and 0.16x debt-to-equity., The full-year loss forecast remains the principal counterpoint to Q1 performance and suggests limited earnings visibility., The JPY0.12bn impairment loss and 141.1% increase in intangible assets make asset recoverability an important monitoring item..

Metrics to watch include Quarterly revenue growth and progress relative to the JPY3.42bn full-year revenue forecast, Gross margin sustainability relative to the Q1 59.2% level, SG&A-to-sales ratio following Q1's decline to 52.3%, Operating-income trajectory versus the full-year JPY1.70bn operating-loss forecast, Recurring earnings excluding impairment and other extraordinary items, Intangible-asset growth, impairment charges, and asset recoverability, Asset retirement obligations relative to liquidity and operational footprint, Annualized ROE and annualized asset turnover.

Regarding relative positioning, CellSource has a notably conservative balance sheet and high liquidity relative to its operating scale, but its annualized 2.2% ROE, 3.8% net margin, and 0.499x asset turnover remain below levels associated with strong profitability. The Q1 margin rebound is encouraging, yet the maintained full-year loss forecast places the company in a transition phase rather than establishing a demonstrated, sustainably profitable earnings profile.